These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 28185577)

  • 1. Artificial neural network classifier predicts neuroblastoma patients' outcome.
    Cangelosi D; Pelassa S; Morini M; Conte M; Bosco MC; Eva A; Sementa AR; Varesio L
    BMC Bioinformatics; 2016 Nov; 17(Suppl 12):347. PubMed ID: 28185577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of Attribute Driven Incremental Discretization and Logic Learning Machine to build a prognostic classifier for neuroblastoma patients.
    Cangelosi D; Muselli M; Parodi S; Blengio F; Becherini P; Versteeg R; Conte M; Varesio L
    BMC Bioinformatics; 2014; 15 Suppl 5(Suppl 5):S4. PubMed ID: 25078098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design of a multi-signature ensemble classifier predicting neuroblastoma patients' outcome.
    Cornero A; Acquaviva M; Fardin P; Versteeg R; Schramm A; Eva A; Bosco MC; Blengio F; Barzaghi S; Varesio L
    BMC Bioinformatics; 2012 Mar; 13 Suppl 4(Suppl 4):S13. PubMed ID: 22536959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Logic Learning Machine creates explicit and stable rules stratifying neuroblastoma patients.
    Cangelosi D; Blengio F; Versteeg R; Eggert A; Garaventa A; Gambini C; Conte M; Eva A; Muselli M; Varesio L
    BMC Bioinformatics; 2013; 14 Suppl 7(Suppl 7):S12. PubMed ID: 23815266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A biology-driven approach identifies the hypoxia gene signature as a predictor of the outcome of neuroblastoma patients.
    Fardin P; Barla A; Mosci S; Rosasco L; Verri A; Versteeg R; Caron HN; Molenaar JJ; Ora I; Eva A; Puppo M; Varesio L
    Mol Cancer; 2010 Jul; 9():185. PubMed ID: 20624283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accurate outcome prediction in neuroblastoma across independent data sets using a multigene signature.
    De Preter K; Vermeulen J; Brors B; Delattre O; Eggert A; Fischer M; Janoueix-Lerosey I; Lavarino C; Maris JM; Mora J; Nakagawara A; Oberthuer A; Ohira M; Schleiermacher G; Schramm A; Schulte JH; Wang Q; Westermann F; Speleman F; Vandesompele J
    Clin Cancer Res; 2010 Mar; 16(5):1532-41. PubMed ID: 20179214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrative genomics reveals hypoxia inducible genes that are associated with a poor prognosis in neuroblastoma patients.
    Applebaum MA; Jha AR; Kao C; Hernandez KM; DeWane G; Salwen HR; Chlenski A; Dobratic M; Mariani CJ; Godley LA; Prabhakar N; White K; Stranger BE; Cohn SL
    Oncotarget; 2016 Nov; 7(47):76816-76826. PubMed ID: 27765905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrative Analysis of DCE-MRI and Gene Expression Profiles in Construction of a Gene Classifier for Assessment of Hypoxia-Related Risk of Chemoradiotherapy Failure in Cervical Cancer.
    Fjeldbo CS; Julin CH; Lando M; Forsberg MF; Aarnes EK; Alsner J; Kristensen GB; Malinen E; Lyng H
    Clin Cancer Res; 2016 Aug; 22(16):4067-76. PubMed ID: 27012812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miRNA expression profiling enables risk stratification in archived and fresh neuroblastoma tumor samples.
    De Preter K; Mestdagh P; Vermeulen J; Zeka F; Naranjo A; Bray I; Castel V; Chen C; Drozynska E; Eggert A; Hogarty MD; Izycka-Swieszewska E; London WB; Noguera R; Piqueras M; Bryan K; Schowe B; van Sluis P; Molenaar JJ; Schramm A; Schulte JH; Stallings RL; Versteeg R; Laureys G; Van Roy N; Speleman F; Vandesompele J
    Clin Cancer Res; 2011 Dec; 17(24):7684-92. PubMed ID: 22031095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An 18 gene expression-based score classifier predicts the clinical outcome in stage 4 neuroblastoma.
    Formicola D; Petrosino G; Lasorsa VA; Pignataro P; Cimmino F; Vetrella S; Longo L; Tonini GP; Oberthuer A; Iolascon A; Fischer M; Capasso M
    J Transl Med; 2016 May; 14(1):142. PubMed ID: 27188717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An integrated cross-platform prognosis study on neuroblastoma patients.
    Chen QR; Song YK; Wei JS; Bilke S; Asgharzadeh S; Seeger RC; Khan J
    Genomics; 2008 Oct; 92(4):195-203. PubMed ID: 18598751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Revised risk estimation and treatment stratification of low- and intermediate-risk neuroblastoma patients by integrating clinical and molecular prognostic markers.
    Oberthuer A; Juraeva D; Hero B; Volland R; Sterz C; Schmidt R; Faldum A; Kahlert Y; Engesser A; Asgharzadeh S; Seeger R; Ohira M; Nakagawara A; Scaruffi P; Tonini GP; Janoueix-Lerosey I; Delattre O; Schleiermacher G; Vandesompele J; Speleman F; Noguera R; Piqueras M; Bénard J; Valent A; Avigad S; Yaniv I; Grundy RG; Ortmann M; Shao C; Schwab M; Eils R; Simon T; Theissen J; Berthold F; Westermann F; Brors B; Fischer M
    Clin Cancer Res; 2015 Apr; 21(8):1904-15. PubMed ID: 25231397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined analysis of RNA-sequence and microarray data reveals effective metabolism-based prognostic signature for neuroblastoma.
    Meng X; Feng C; Fang E; Feng J; Zhao X
    J Cell Mol Med; 2020 Sep; 24(18):10367-10381. PubMed ID: 32683778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subclassification and individual survival time prediction from gene expression data of neuroblastoma patients by using CASPAR.
    Oberthuer A; Kaderali L; Kahlert Y; Hero B; Westermann F; Berthold F; Brors B; Eils R; Fischer M
    Clin Cancer Res; 2008 Oct; 14(20):6590-601. PubMed ID: 18927300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A five-gene signature derived from m6A regulators to improve prognosis prediction of neuroblastoma.
    Wang Z; Cheng H; Xu H; Yu X; Sui D
    Cancer Biomark; 2020; 28(3):275-284. PubMed ID: 32176634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypoxia Predicts Poor Prognosis in Neuroblastoma Patients and Associates with Biological Mechanisms Involved in Telomerase Activation and Tumor Microenvironment Reprogramming.
    Cangelosi D; Morini M; Zanardi N; Sementa AR; Muselli M; Conte M; Garaventa A; Pfeffer U; Bosco MC; Varesio L; Eva A
    Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32825087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 3-Protein Expression Signature of Neuroblastoma for Outcome Prediction.
    Xie Y; Xu H; Fang F; Li Z; Zhou H; Pan J; Guo W; Zhu X; Wang J; Wu Y
    Am J Surg Pathol; 2018 Aug; 42(8):1027-1035. PubMed ID: 29794872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A signature of 29 immune-related genes pairs to predict prognosis in patients with neuroblastoma.
    Song J; Zhao Q; Xu Y; Zhu L
    Int Immunopharmacol; 2020 Nov; 88():106994. PubMed ID: 33182060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypoxia-induced dedifferentiation of tumor cells--a mechanism behind heterogeneity and aggressiveness of solid tumors.
    Axelson H; Fredlund E; Ovenberger M; Landberg G; Påhlman S
    Semin Cell Dev Biol; 2005; 16(4-5):554-63. PubMed ID: 16144692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene-expression-based analysis of local and metastatic neuroblastoma variants reveals a set of genes associated with tumor progression in neuroblastoma patients.
    Nevo I; Oberthuer A; Botzer E; Sagi-Assif O; Maman S; Pasmanik-Chor M; Kariv N; Fischer M; Yron I; Witz IP
    Int J Cancer; 2010 Apr; 126(7):1570-81. PubMed ID: 19739072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.